政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/80625
English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  全文筆數/總筆數 : 113393/144380 (79%)
造訪人次 : 51234284      線上人數 : 934
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    政大機構典藏 > 理學院 > 心理學系 > 期刊論文 >  Item 140.119/80625


    請使用永久網址來引用或連結此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/80625


    題名: Hepatitis B virus: new therapeutic perspectives
    作者: Lin, Chih-Lin
    林志陵
    Yang, Hung-Chih
    Kao, Jia-Horng
    貢獻者: 心理系
    日期: 2016-01
    上傳時間: 2016-01-15 15:54:22 (UTC+8)
    摘要: Current antiviral therapies have dramatically improved the long-term outcomes of patients with chronic hepatitis B virus ( HBV) infection. Both interferon ( IFN) and nucleos(t)ide analogue ( NA) treatments have been shown to reduce the progression of liver disease in chronic hepatitis B ( CHB) patients. However, persistent covalently closed circular DNA (ccc DNA) can result in a viral relapse after discontinuation of antiviral treatment. On the basis of extensive research on the HBV lifecycle and virus-host interactions, several new agents focusing on viral and host targets are under development to cure HBV. New polymerase inhibitors, tenofovir alafenamide and besifovir provide effective and safer treatment for CHB patients. Agents targeting ccc DNA, such as engineered site-specific nucleases and RNA interference therapeutics could eliminate ccc DNA or silence ccc DNA transcription. Inhibitors of HBV nucleocapsid assembly suppress capsid formation and prevent synthesis of HBV DNA. The HBV entry inhibitor, Myrcludex-B, has been shown to effectively inhibit amplification of ccc DNA as well as the spread of intrahepatic infection. Agents targeting host factors that enhance innate and adaptive immune responses, including the lymphotoxin-β receptor agonist, toll-like receptor agonist, immune checkpoint inhibitors and adenovirus-based therapeutic vaccine, could play a critical role in the elimination of HBV-infected cells. With all of these promising approaches, we hope to reach the ultimate goal of a cure to HBV in the near future.
    關聯: Liver International, 36, 85-92
    資料類型: article
    DOI 連結: http://dx.doi.org/10.1111/liv.13003
    DOI: 10.1111/liv.13003
    顯示於類別:[心理學系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    85-92.pdf1261KbAdobe PDF2622檢視/開啟


    在政大典藏中所有的資料項目都受到原著作權保護.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋